Adiponectin is an adipocytokine that signals through plasma membrane-bound adiponectin receptors 1 and 2 (AdipoR1 and -2). Plasma adiponectin depletion is associated with type 2 diabetes, obesity, and cardiovascular diseases. Adiponectin therapy, however, is yet unavailable owing to its large size, complex multimerization, and functional differences of the multimers. We report discovery and characterization of 6-C-b-D-glucopyranosyl-(2S,3S)-(+)-5,7,39,49-tetrahydroxydihydroflavonol (GTDF) as an orally active adiponectin mimetic. GTDF interacted with both AdipoRs, with a preference for AdipoR1. It induced adiponectin-associated signaling and enhanced glucose uptake and fatty acid oxidation in vitro, which were augmented or abolished by AdipoR1 overexpression or silencing, respectively. GTDF improved metabolic health, characterized by elevated glucose clearance, b-cell survival, reduced steatohepatitis, browning of white adipose tissue, and improved lipid profile in an AdipoR1-expressing but not an AdipoR1-depleted strain of diabetic mice. The discovery of GTDF as an adiponectin mimetic provides a promising therapeutic tool for the treatment of metabolic diseases.
The anti-inflammatory adipocytokine adiponectin (1, 2) signals through adiponectin receptors 1 and 2 (AdipoR1 and -2) (3). T-cadherin, a cadherin family member that lacks transmembrane and cytoplasmic domains, also binds adiponectin and is proposed to affect its bioavailability (4) . Plasma adiponectin depletion is associated with type 2 diabetes, obesity, and cardiovascular diseases (5-7). Adiponectin administration or overexpression ameliorates insulin resistance, metabolic syndrome, and atherosclerosis in animals (3, (8) (9) (10) (11) (12) and enhances pancreatic b-cell survival (13) . This evidence makes AdipoRs important therapeutic targets for metabolic diseases.
Structurally, adiponectin belongs to the complement 1q family (1, 14, 15) . Adiponectin monomer is a 30-kDa protein consisting of an N-terminal collagenous domain and a COOH-terminal globular domain (1) . Mammalian plasma adiponectin is present in several multimeric forms, low-molecular-weight dimer or trimers, mediummolecular-weight hexamers, or high-molecular-weight (HMW) dodecamers and 18 mers (10, (16) (17) (18) . The globular domain of adiponectin (gAd) can form trimers and was initially shown to exist as a proteolytic cleavage product in human plasma (10) ; although subsequent studies failed to detect it in circulation, its ability to modulate AdipoRs is undisputed. All these forms display different levels of physiological activity, and the HMW complex is considered the most clinically relevant form (10, (16) (17) (18) . The HMW full-length adiponectin and gAd preferentially signal through AdipoR2 and AdipoR1, respectively (3) . Given the multimerization-related complexities of adiponectin structure and function, it appears that small molecule AdipoR ligands may provide the only viable therapeutic option against diseases associated with defects in adiponectin expression or action.
We have previously identified 6-C-b-D-glucopyranosyl-(2S,3S)-(+)-39,49,5,7-tetrahydroxyflavonol (GTDF), a novel natural analog of the dietary flavonoid quercetin, as a potent orally bioavailable osteoanabolic compound that induced proliferation, differentiation, and mineralization of cultured primary osteoblasts at a nanomolar concentration that was 1,000-fold less than the effective concentration of quercetin or queretin-O-glucoside and restored trabecular bones of osteopenic rats on par with parathyroid hormone (19) . While studying its mechanism of action, we found that GTDF induced rapid AMP-dependent protein kinase (AMPK), AKT, and p38 phosphorylation and elevated PPARg coactivator-1a (PGC-1a) expression in osteoblasts. GTDF also deacetylated tumor suppressor P53 via indirect activation of NAD-dependent deacetylase Sirtuin1 (Sirt1) (S.Sa., N.C., unpublished observations, and Khan et al. [20] ). Literature search revealed that adiponectin elicits similar cellular signaling (1, 3, 11) . Interestingly, the quercetin group of compounds display functional properties similar to adiponectin, such as AMPK activation, glucose uptake enhancement, induction of fatty acid oxidation-related genes, and amelioration of diabetes and insulin resistance in vivo (21, 22) . We thus asked if GTDF, quercetin, or other naturally occurring quercetin analogs could be adiponectin mimetics. Here we report detailed characterization of GTDF as an adiponectin mimetic that improves metabolic health in a rodent model of diabetes.
RESEARCH DESIGN AND METHODS

Materials and Kits
All cell culture reagents were from Invitrogen, Life Technologies (Carlsbad, CA). Fine chemicals were from SigmaAldrich (St. Louis, MO) unless otherwise indicated. Epoxy agarose beads conjugated with GTDF were constructed at Shantani Biotech (Pune, India). gAd was purchased from Enzo Life Sciences (Farmingdale, NY) and ATGen Global (Gyeonggi-do, South Korea) and compared. gAd from both sources showed identical activity. gAd from ATGen Global was used in this study. GW7647 was from Sigma-Aldrich, and full-length human AdipoR1 and AdipoR2 mammalian expression constructs were from Open Biosystems (Huntsville, AL).
125
I-gAd was from Phoenix Pharmaceuticals (Burlingame, CA), and 125 I (20 MBq) used for radiolabeling GTDF was from BARC (Mumbai, India). Glycogen assay kit was from Sigma-Aldrich. Serum concentrations of triglycerides (TGs), nonesterified free fatty acids (NEFAs), HDL, LDL, VLDL, total cholesterol, b-hydroxybutyrate, and creatinine were determined using kits purchased from Pointe Scientific (Canton, MI). Circulating glucagon, insulin, C-peptide, leptin, adiponectin, ghrelin, corticosterone, and markers of inflammation (monocyte/macrophage chemoattractant protein-1 [MCP-1], tumor necrosis factor-a [TNF-a], and interleukin 6 [IL-6]) were estimated using ELISA assay kits (R&D Systems, Minneapolis, MN). Serum concentrations of sodium and potassium were measured using a Cobas c system (Roche Diagnostics, Indianapolis, IN). TUNEL assay kit was from Roche Applied Science (Indianapolis, IN). Plasma membrane (PM) extraction kit was from BioVision (Milpitas, CA).
Cell Culture and Induction of Differentiation HEK-293, CHO, C2C12, and 3T3L-1 cell lines were cultured as previously reported (23) . Mouse stromal vascular fraction (SVF) was prepared from epididymal fat pad by collagenase digestion. Human SVFs were prepared from human lipoaspirates (subcutaneous), collected after approval of the institutional ethics committee. Cells were differentiated in the presence of GTDF or vehicle for 10 days (3T3L-1 and mouse SVF) or 21 days (human SVF) using standard procedure and then analyzed by quantitative PCR (QPCR), immunoblotting, or microscopy.
Iodination and Purification of 125 I-GTDF GTDF was radiolabeled as previously described for quercetin with minor modifications. In brief, 10 mL 125 I (20 MBq) was added to 100 mg GTDF in 5% acetic acid/methanol, chloramine-T (4 mg in Milli-Q H 2 O) was added, and the mixture was allowed to react at room temperature (24°C) for 5 min. The reaction was terminated by adding 60 mL sodium metabisulphite (4 mg/mL in Milli-Q H 2 O). The reaction mixture was dried by passing nitrogen and was dissolved into methanol (100 mL). Reverse-phase thin-layer chromatography (TLC) (RP-18 F254s, 8 cm in length; Merck) was used to purify 125 I-GTDF from free iodine and unlabeled compound using methanol-water (40-60%) as mobile phase. After run, the TLC plate was cut into pieces of 0.5 mm each, and the distribution of radioactivity along the plate was measured in a gamma counter. TLC of the blank reaction suggested the location of free 125 I in the TLC plate. The RF value of the labeled compound was determined by gamma counting. The area showing maximum activity at distance of 40-60 mm was eluted from the TLC plate and was washed with methanol, centrifuged, decanted, and dried under N 2 .
Overexpression and Silencing Experiments
Plasmid transfections were performed with Lipofectamine LTX (Life Technologies) reagent according to the manufacturer's protocols. For C2C12 transfections, C2C12 myoblasts were trypsinized and transfected. The cells were then grown until 60-70% confluence. They were then differentiated and assessed as required. For RNA interference, small interfering RNAs (siRNAs) (siAdipoR1; L-063377-01-0010 and siC; siRNA against luciferase GL3 duplex D-001400-01-50) were purchased from Thermo Scientific (Pittsburgh, PA). Cells were transfected with 0.1 mmol/L of each siRNA using DharmaFECT 1 transfection reagent (Thermo Scientific). Seventy-two hours after transfection, cells were treated and analyzed as required.
QPCR, Western Blotting, Coimmunoprecipitation
These studies were performed as previously described (23) . The list of primer sequences for QPCR has been provided in Supplementary Table 5 . Anti-PGC-1a (ST1202; Millipore, Billerica, MA) was used at 1:2,000 dilution, and anti-CD36 (18836-1-AP; Proteintech, Chicago, IL) was used at 1:1,000 dilution. Anti-UCP-1 (ab10983), -UCP-3 (ab3477), and -PPARa (ab8934) (Abcam, Cambridge, MA) were used at 1:1,000 dilutions. Phospho-AMPK (Thr172), AMPK, phospho-p38 (Thr 180/Tyr 182), p38, phospho-ACC, acetyl coA carboxylase (ACC), glucose transporter 4 (Glut4), P53, acetyl-P53 (Lys 382), ccaat/enhancer protein b (C/EBPb), and b-actin antibodies were from Cell Signaling Technology (Beverly, MA) and were used at 1:1,000, except b-actin, which was used at 1:3,000 dilution. Antibodies against AdipoR1 (sc-46748), AdipoR2 (sc-46755), and N-cadherin (sc-1502) were from Santa Cruz Biotechnology (Dallas, TX) and used at 1:1,000 dilutions. For immunohistochemistry, insulin antibody (Cell Signaling Technology) was used at a dilution of 1:200, phycoerythrintagged Ki-67 antibody (BD Biosciences, San Diego, CA) was used at a dilution of 1:100, and anti-UCP-1 (ab10983) was used at a dilution of 1:250. Following detection with one antibody, Western blots were stripped and reprobed with other antibodies whenever possible.
Glucose Uptake
Fully differentiated C2C12 myotubes on 24-well plates were treated with vehicle (0.1% DMSO) or 0.01 mmol/L GTDF for 24 h, after which the cells were serum starved for 3 h. The cells were then washed three times in warm (37°C) HEPES buffer solution (HBS; 140 mmol/L sodium chloride, 20 mmol/L HEPES, 5 mmol/L potassium chloride, 2.5 mmol/L magnesium sulfate, 1 mmol/L calcium chloride, pH 7.4) and then were treated with warm HBS or 0.1 mmol/L insulin (in HBS) for 20 min. Subsequently, cells were washed three times in warm HBS and then incubated in 250 mL transport solution (HBS containing 1 mCi 3H-deoxyglucose [PerkinElmer] and 10 mmol/L unlabeled 2-deoxyglucose [Sigma-Aldrich]) per well for 5 min. Then the transport solution was aspirated and the cells were washed three times with ice-cold stop solution (0.9% NaCl and 25 mmol/L dextrose). Subsequently, the cells were lysed in 100 mL 0.5 N NaOH, and 5 mL lysate was used for determination of protein concentration (by bicinchoninic acid assay; Sigma-Aldrich), and the rest of the lysate was used to measure cellular radioactivity in a beta counter (Beckman Coulter, New Delhi, India).
Fatty Acid Oxidation
C2C12 myotubes plated in 12-well plates were treated with vehicle (0.1% DMSO) or 0.01 mmol/L GTDF for 2, 24, or 120 h. After treatment, the cells were washed three times in warm HBS and were then incubated with medium containing 0.75 mmol/L palmitate (conjugated to 2% fatty acid-free BSA/[ 14 C]palmitate at 2 mCi/mL) for 2 h. After this incubation period, 1 mL of the culture medium was removed and transferred to a sealable tube, the cap of which housed a Whatman (GF/B) filter paper disc that had been presoaked with 1 mol/L potassium hydroxide.
14 CO 2 trapped in the media was then released by acidification of media using 60% (volume for volume) perchloric acid and gently agitating the tubes at 37°C for 2 h. Radioactivity that had become adsorbed onto the filter discs was then quantified by liquid scintillation counting in a beta counter.
Animal Experiments
Animal studies were approved by the Institutional Animal Ethics Committee of Zydus Research Center. This facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Mice were individually housed at 21°C, in 12-h light/dark cycles. All animals had access to normal chow diet and water ad libitum. Twelve-week-old male C57BL/6J (BL6) (25-30 g ), db/db, or BKS-db/db (45-50 g) mice were divided into different treatment groups randomly (db/db, n = 8 per group; BKS-db/db, n = 6 per group). Vehicle groups received 1% carboxymethylcellulose, and the other groups received GTDF or pioglitazone (Pio; 10 mg/kg), once a day, by oral gavage for 30 days. Feed intake and body weight were measured every day. Blood was obtained from tail snips, and glucose levels were measured using a glucometer. Glucose tolerance tests were performed on day 29 after overnight fasting. Pyruvate tolerance test (PTT) was performed on day 31, after an overnight fast. On day 32, the animals were fasted for 6 h and killed. Plasma and tissues were collected and stored at 280°C until further analysis. Hepatic glycogen was estimated using a glycogen assay kit. Intraperitoneal glucose tolerance test (IPGTT), intraperitoneal PTT, estimation of circulating biomarkers, histology, and immunohistochemistry were performed using standard procedures.
Extensor Digitorum Longus Muscle Culture and Treatment
Extensor digitorum longus (EDL) muscle strips along with tendons were dissected out from anesthetized mice and were tied to stainless steel clutch pins by the tendons, without stretching. Muscles were preincubated for 30 min at 37°C in oxygenated (95% O 2 /5% CO 2 ) Krebs-Henseleit solution (pH 7.4) and then again for 30 min in the same medium with or without 2.5 mg/mL gAd or 0.1 mmol/L GTDF. The incubation media was gassed continuously with 95% O 2 /5% CO 2 through hypodermic needle. At the end of this incubation, tendons were removed and the muscles were blotted on gauze pads, snap frozen in liquid N 2 , and stored at 280°C until further analysis.
Data Analysis and Statistics
Results are expressed as mean 6 SEM. All data were analyzed using GraphPad Prism 5.0 (GraphPad, San Diego, CA). Animal data involving more than two groups were analyzed using two-way ANOVA followed by Bonferroni post test or one-way ANOVA followed by Tukey multiple comparison test as appropriate. In vitro or in vivo data involving two experimental groups were analyzed using two-tailed unpaired Student t test or Mann-Whitney U test as appropriate.
RESULTS
GTDF Binds to AdipoRs and Mimics AdiponectinAssociated Signaling Events In Vitro
We assessed GTDF, quercetin, and its natural analogs (chemical structures in Fig. 1 ) in a peroxisome proliferatoractivated receptor-a (PPARa) ligand activation assay, a previously reported functional assay for AdipoRs (3), in HEK293 cells that express endogenous AdipoR1 (3) . All the quercetin analogs tested enhanced PPARa activity in the presence of PPARa agonist GW7647 ( Fig. 2A) . GTDF maximally activated the reporter at 0.01 mmol/L, whereas dihydroquercetin (DHQ), an enantiomer of the aglycone form of GTDF and quercetin-6-C-b-D-glucopyranoside (QCG), did so at 0.1 mmol/L, and quercetin, quercetin- Fig. 2A) . Amplitudes of activation of PPARa ligand activity by GTDF and gAd were comparable (Fig. 2B ). GTDF did not activate PPARa in the absence of GW7647, indicating that it was not a PPARa agonist per se (Fig. 2C) .
To assess if GTDF and AdipoRs could physically interact, we immobilized GTDF on agarose beads and performed a pull-down assay with purified PM from C2C12 myotubes that expressed both AdipoR1 and -2 (3). GTDF beads but not control beads successfully pulled down AdipoR1 and -2, and free GTDF or QCG competed with this binding ( Consistent with adiponectin-associated rapid signaling events (1, 25) , GTDF induced AMPK, ACC, and p38 phosphorylation in C2C12 myotubes (Fig. 2H) . Whereas p38 phosphorylation was rapid and sustained, AMPK and ACC phosphorylation peaked at 1 and 10 min, respectively, and returned to the basal level at 60 min (Fig. 2H) . A similar pattern of AMPK and ACC phosphorylation by adiponectin has been reported earlier (11) .
Apart from adiponectin, glutamate receptors also activate AMPK and p38 (26) , and we therefore assessed if GTDF could modulate these receptors. However, GTDF failed to bind to or activate/repress any of the ionotropic or metabotropic glutamate receptors (mGlu), whereas quercetin strongly activated mGlu2 and inhibited mGlu4, -6, and -8 ( Supplementary Tables 1 and 2 ). To also assess if these signaling events were mediated through one or more G protein-coupled receptors (GPCRs), GPCR modulation by GTDF was assessed, and it failed to activate or repress any of the 158 GPCRs tested (Supplementary Tables  3 and 4) .
Consistent with its activation of adiponectin-associated signaling, GTDF 2I and J) . Adiponectin deacetylates and activates PGC-1a via indirect activation of Sirt1 (25) , and consistent with its indirect Sirt1 activation (20) , GTDF also deacetylated PGC1a in C2C12 myotubes (Fig. 2K ). This PGC-1a induction and activation led to increased mitochondrial DNA copy number (Fig. 2L) . gAd enhances basal glucose uptake (3, 11) and increases insulin sensitivity (27) in C2C12 myotubes, and in consistence, GTDF also enhanced basal and insulin-stimulated glucose uptake in these cells (Fig. 2M) . Further, GTDF also significantly enhanced basal and insulin-dependent glucose uptake in a C2C12 myotube model of palmitate-induced insulin resistance (Fig. 2N) . Similar to rapid enhancement of fatty acid oxidation by adiponectin (3, 11, 28) , GTDF significantly enhanced [ 14 C]palmitate oxidation in C2C12 myotubes within 2 h, which increased further over time (Fig. 2O) .
Overexpression or Silencing of AdipoR1 Augments or Mitigates GTDF Functions In Vitro
Consistent with the binding studies, AdipoR1 but not AdipoR2 overexpression in C2C12 myotubes significantly enhanced GTDF-stimulated AMPK, ACC, and p38 phosphorylation (Fig. 3A) . siRNA for AdipoR1 (siAdipoR1) but not control siRNA against luciferase (siC) abolished GTDF-induced AMPK, ACC, and p38 phosphorylation, without affecting AdipoR2 expression (Fig. 3B) . Further, GTDFstimulated glucose uptake and fatty acid oxidation were abolished by siAdipoR1 (Fig. 3C and D) , whereas insulinstimulated glucose uptake was unaltered (Fig. 3D) . Together A relevant animal model to test AdipoR specificity of GTDF would have been AdipoR1/R2 knockout mice subjected to diet-induced obesity. However, our inability to obtain the knockout mice led us to search for an alternate model. Since chronic high level of plasma insulin causes an AdipoR depletion-mediated adiponectin resistance (30), we systematically investigated AdipoR expression in major adiponectin target organs, across different age-groups in two different strains of leptin receptordeficient obese and diabetic mice, db/db (in C57BL/6J background) and BKS-db/db (in BLKS/J background), and wild-type healthy C57BL/6J (BL6).
Comparison of 12-week-old male BL6, db/db, and BKSdb/db mice revealed that both diabetic mice had lower AdipoR mRNAs in skeletal muscle, liver, and epididymal white adipose tissue (eWAT) compared with the healthy BL6 mice. However, between the diabetic strains, only modest differences were observed (Fig. 4A) .
Examination of total and PM-associated AdipoR protein levels however, revealed striking differences between the two diabetic strains. Whereas BKS-db/db displayed .80% decrease in total and PM-associated and therefore functional AdipoR1 expression in skeletal muscle, BL6 and db/db did not show a significant difference (Fig. 4B) . In liver, PM AdipoR1 but not AdipoR2 was strongly depleted ($80%) in BKS-db/db but not in db/db, whereas compared with BL6, total AdipoR1 and -2 proteins were diminished in both. In WAT, both diabetic strains displayed .90% reduction in total AdipoR1 protein compared with BL6, whereas AdipoR2 protein was not detected (Fig. 4B ). AdipoR2 could not be detected in the PM fraction of skeletal muscle (Fig. 4B) , and we failed to generate enough PM extract from WAT for immunoblotting. Together, compared with db/db and BL6, BKS-db/db displayed severely depleted total and PM AdipoR1 protein in skeletal muscle and liver at 12 weeks of age. Consistent with this observation, gAd and GTDF failed to induce AMPK phosphorylation in EDL muscles of BKS-db/db, whereas it did so in EDL muscles from both BL6 and db/db mice (Fig. 4C) . Thus, based on above evidence, we selected 12-week-old male db/db mice as adiponectin-sensitive and age-and sex-matched BKS-db/db as adiponectin-resistant models for the in vivo pharmacological studies.
GTDF Fails to Improve Diabetic Phenotype in BKS-db/db Mice
Over a 30-day treatment period, GTDF did not alter feed intake or body weight in BKS-db/db (Fig. 5A and B) , whereas PPARg agonist Pio significantly enhanced body weight 6 days onwards without altering feed intake GTDF, QCG, and DHQ were isolated from the stem bark of Ulmus wallichiana Planchon (19, (48) (49) (50) . QR was prepared from stems of Cissus quadrangularis (51). Quercetin and QOG were procured from Sigma-Aldrich. Purity of GTDF, DHQ, QCG, and QR were >98%; quercetin was >95%; and QOG was >90%. Comparison of GTDF with gAd (0.1 mg/mL). C: GTDF activity in absence of GW7647. D: GTDF was immobilized on epoxy agarose beads, and GTDF beads or mock-treated control beads were incubated with 50 mg PM extracts from C2C12 myotubes in presence or absence of 100-fold molar excess of GTDF or QCG. After washes, the complexes were resolved by SDS-PAGE and were analyzed by immunoblotting (see Supplementary Fig. 1 for antibody validation data; anti-AdipoR1 also detected AdipoR2 in agreement with the supplier information). E: Competition radioligand binding assay. C2C12 myotubes in 12-well plates were incubated with 2 mL of 10 mCi/mL mouse 125 I-gAd with or without cold GTDF in PBS supplemented with 0.1% BSA for 12 h, after which cells were washed and lysed. A portion of the lysate was used for protein estimation, and the rest was ( Fig. 5A and B) . GTDF failed to alter nonfasting blood glucose, fasting blood glucose, and glucose clearance, whereas Pio significantly improved these parameters ( Fig. 5C and D) . GTDF failed to alter plasma glycated hemoglobin (HbA 1c ) and insulin ( Fig. 5E and F) . GTDF was ineffective in improving the fasting lipid profile in quantitated in a gamma counter. Nonspecific binding was determined with a 200-fold excess of cold gAd. Specific binding was calculated by subtracting nonspecific binding from the total binding. The count per minute was normalized with protein concentration and plotted as % binding compared with wells without cold GTDF. F:
125 I-GTDF was prepared by chloramine T method as described elsewhere (52) I did not move in the TLC with mobile-phase methanol water (40-60%). G: CHO cells transfected with AdipoR1, AdipoR2, or empty expression plasmids in 12-well plates were incubated with increasing concentrations of 125 I-GTDF (specific activity 178.2 Ci/mmol) for 2 h at 4°C (at 2 h, the binding equilibrium was established). The cells were then washed and processed as in F. H: Immunoblot analysis in C2C12 myotubes treated with or without GTDF for indicated times. Densitometric analysis of three independent blots using ImageJ software is given in the right panel. I: QPCR-based determination of gene expression in C2C12 myotubes was performed on a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) using SYBR green chemistry (oligonucleotide sequences in Supplementary Table 5 ). Data were analyzed by DDCT method using b-actin as normalization control. J: Immunoblotting in C2C12 myotubes treated with GTDF. K: Coimmunoprecipitation followed by immunodetection of acetylated PGC-1a. Whole-cell extracts from C2C12 myotubes were precleared with protein-A sepharose and IgG isotype and were incubated with PGC-1a antibody (2 mg/reaction) for 3 h. Complexes were resolved on 8% SDS-PAGE and probed with AcLys antibody. L: Mitochondrial DNA content determination by QPCR in C2C12 myotubes treated for 48 h with GTDF. M: Glucose uptake in C2C12 myotubes. C2C12 myotubes in 24-well plates were treated with vehicle or GTDF for 24 h. Cells were then washed and treated with 0.1 mmol/L insulin for 20 min, and glucose uptake was quantified as described in RESEARCH DESIGN AND METHODS. N: C2C12 myotubes were rendered insulin resistant by incubation in 500 mmol/L palmitate for 24 h (control groups received 4% BSA). GTDF group received 0.01 mmol/L GTDF for 12 h. Glucose uptake studies were performed as described in M. O: Fatty acid oxidation in C2C12 myotubes. C2C12 myotubes in 12-well plates were treated with vehicle or GTDF. After incubation, fatty acid oxidation was assessed as described in RESEARCH DESIGN AND METHODS. Data are mean 6 SEM of three (A-C, E, G-I, K, and M-O) or six independent experiments (L). All images are representatives of three independent experiments. GTDF concentration in all experiments was 0.01 mmol/L or as indicated. V, vehicle. *P < 0.05; **P < 0.01; ***P < 0.001. Densitometry data are mean 6 SEM of three independent images. GTDF concentration in all experiments was 0.01 mmol/L. Note that anti-AdipoR1 also detects AdipoR2. *P < 0.05; **P < 0.01; ***P < 0.001. these mice, whereas Pio modestly but significantly reduced plasma TG and VLDL (Fig. 5G) . These results indicate that GTDF is ineffective in BKS-db/db mice that display severely depleted AdipoR1 protein in skeletal muscle and liver. That Pio improved glycemic parameters in these mice further indicates that GTDF did not function through the PPARg pathway.
GTDF Ameliorates Diabetic Phenotype in AdipoR1-Expressing db/db Mice
In contrast to its inefficacy in BKS-db/db (Fig. 5) , GTDF was remarkably effective in AdipoR1-expressing db/db mice. It reduced feed intake in db/db but not BL6 (Fig. 6A) , which could be correlated with a robust reduction in serum ghrelin (Fig. 6N) . GTDF-treated db/db mice displayed a reducing trend in body weight, which however was not statistically significant (Fig. 6B) , and showed significantly reduced adipose tissue weight (Supplementary Fig. 3 ). GTDF remarkably reduced nonfasting blood glucose in db/db mice on the 7th day of treatment (Fig. 6C) . Reduction in feed intake could not be responsible for the GTDF-induced reduction in nonfasting glucose level in db/db, as the feed intake was significantly different only after 16 days of treatment, whereas nonfasting blood glucose was drastically reduced at the 7th day and did not fall any further.
GTDF modestly yet significantly reduced fasting blood glucose in db/db but not in BL6 (Fig. 6D) , which was Figure 4 -Comparison of mRNA and protein expression of AdipoRs and evaluation of adiponectin sensitivity in BL6, db/db, or BKS-db/db mice. Male mice (12 weeks old; n = 3 per group) were assessed for AdipoR mRNA expression (A) and total or PM-associated AdipoR protein levels (B) in skeletal muscle (quadriceps), liver, or eWAT. Bar graphs represent densitometric analysis. b-Actin and N-cadherin were used as loading controls. Note that anti-AdipoR1 also detects AdipoR2. C: EDL muscles excised from 12-week-old BL6, db/db, or BKS-db/db mice were treated with gAd, GTDF, or vehicle for 30 min as described in RESEARCH DESIGN AND METHODS. Total protein was then isolated and analyzed for pAMPK and AMPK expression. *P < 0.05; **P < 0.01; ***P < 0.001 in comparison with BL6. ## associated with modestly reduced hepatic gluconeogenesis, as revealed by a PTT (Fig. 6E) . GTDF treatment prevented increase in HbA 1c in db/db, which increased in the vehicletreated db/db during the treatment period (Fig. 6F) . In IPGTT, GTDF-treated db/db mice showed remarkably improved glucose clearance (Fig. 6G) . However, both fasting insulin as well as insulin levels during glucose challenge were higher in these mice over vehicle-treated controls, whereas they were unchanged in BL6 mice (Fig. 6G-I) . The enhanced insulin level was associated with increase in pancreatic C-peptide (Fig. 6J) , indicating that insulin production was higher in GTDF-treated db/db mice. However, hypokalemia, generally associated with higher insulin, was not observed (Fig. 6K) .
Pancreatic histomorphometry revealed that in vehicletreated db/db mice, islet number was diminished in comparison with BL6, and GTDF significantly increased it in the former but not latter (Fig. 6L and M) . Furthermore, ;30% of the b-cell population in the islets of vehicletreated db/db mice were apoptotic, as determined by TUNEL staining, whereas GTDF markedly attenuated the number of apoptotic b-cells (Fig. 6L and M) . The increased islet number in GTDF-treated db/db pancreas was not due to cellular proliferation as the islets from these mice did not stain for the proliferation marker Ki-67 (Fig.  6L) , indicating that GTDF might protect b-cells from gluco-and lipotoxicity-induced apoptosis. Serum glucagon level was unchanged (Fig. 6N) . Figure 5 -GTDF but not Pio fails to improve metabolic health in BKS-db/db. Male BKS-db/db mice (12 weeks old; n = 6 per group) were fed vehicle, 10 mg/kg GTDF, or Pio for 30 days. A: Feed intake. B: Body weight. C: Nonfasting blood glucose was analyzed using a glucometer capable of measuring 20-900 mg/dL glucose in whole blood (Gluco.Dr SuperSensor; All Medicus Co. Ltd., Gyeonggi-do, South Korea). D: IPGTT. Glucose was intraperitoneally administered in mice (1 g/kg body weight), and at indicated time points, blood was collected from tail snips and blood glucose was measured by a glucometer. The right panel represents area under the curve (AUC). E: Glycated hemoglobin level; vehicle vs. GTDF, 9.9 6 0.4 vs. 9.3 6 0.3% (84.33 6 4.29 vs. 78.17 6 2.96 mmol/mol). F: Fasting insulin was estimated by ELISA. G: Fasting serum lipid profile. *P < 0.05; **P < 0.01; ***P < 0.001. Figure 6 -GTDF improves metabolic parameters in db/db mice. db/db or BL6 mice (12 weeks old) were fed vehicle or 10 mg/kg GTDF for 30 days; n = 8 per group. A: Feed intake. B: Body weight. C: Nonfasting blood glucose. D: Fasting blood glucose. E: PTT. Mice were intraperitoneally administered sodium pyruvate (1 g/kg body weight), and blood collected from tail snips was analyzed by a glucometer. Inset represents area under the curve (AUC). F: Glycated hemoglobin level; graph represents mean 6 SEM. HbA 1c was comparable between vehicle and GTDF group on 0 days (mean 6 SD, 8.7 6 1.03 vs. 8.72 6 1.17%; 72.0 6 11.1 vs. 72 6 12.8 mmol/mol) but was significantly lowered in GTDF-treated group after 30 days vehicle (V) vs. GTDF (10.53 6 0.54 vs. 9 6 0.93%; 91 6 5.9 vs. 75 6 10.2 mmol/mol). G: IPGTT; inset represents AUC. H: Insulin level during IPGTT. Blood collected from tail snips at indicated time points during GTT was used for insulin measurement by ELISA. Inset represents AUC. I: Fasting insulin. J: Serum pancreatic C-peptide level. K: Serum Na + and K + levels. L: Microscopic images from immunostaining of pancreas sections by anti-insulin antibody. Diaminobenzidine staining (light microscopy; Leica DMI6000 B) (top two panels); confocal microscopy (Carl Zeiss LSM 510 Meta) (third and fourth panels). Immunofluorescence for insulin (green), DAPI (blue), and TUNEL (red), or insulin, DAPI, and Ki-67 (red) by confocal microscopy are shown. M: Histomorphometry of pancreatic islets was performed using Image-Pro Plus (6.1) software (Media Cybernetics), where two investigators separately evaluated 10 random sections probed with insulin antibody from four mice per group, blinded to experimental design. N: Fasting serum levels of circulating glucagon, leptin, adiponectin, ghrelin, corticosterone, and markers of inflammation (MCP-1, TNF-a, and IL-6) as determined by ELISA. O: Microscopic images from hematoxylin and eosin (H&E)-or Oil Red O-stained liver sections. Top panels: original magnification 310; bar 200 mm. Middle and bottom panels original magnification 340; bar 50 mm. P: Hepatic glycogen content. n = 8 for all experiments unless otherwise indicated. *P < 0.05; **P < 0.01; ***P < 0.001.
Consistent with anti-inflammatory properties of adiponectin, GTDF treatment in db/db mice significantly lowered serum TNF-a and IL-6 showed a reducing trend, whereas MCP-1 was unchanged (Fig. 6N) . Whereas serum adiponectin showed an increasing trend upon GTDF treatment (P = 0.082), leptin level was greatly diminished (Fig. 6N) . We also found a robust fall in serum corticosterone (Fig. 6N) , indicating that GTDF might be cardioprotective. Analysis of serum lipid profile revealed significant reductions in total cholesterol, TG, VLDL, NEFAs, and ketone bodies (b-OH butyrate), which supports an enhanced fatty acid oxidation rate, whereas it significantly enhanced HDL level (Fig. 6N) , reiterating its cardioprotective promise. LDL and creatinine levels were unchanged (Fig. 6N) . In light of the lipid profile data, we examined the hepatic histology, and sections from GTDF-treated db/db mice displayed no vacuolation and lipid accumulation, whereas the vehicle-treated db/db exhibited robust lipid accumulation (Fig. 6O) . Hepatic glycogen level was unchanged (Fig. 6P) . Together, Figs. 5 and 6 indicated that GTDF stalls diabetes progression in AdipoR-expressing db/db mice and improves their overall metabolic health, whereas it is ineffective in AdipoR1-depleted BKS-db/db.
GTDF Induces Browning of WAT, Evidence of Involvements of Direct and Indirect Pathways
GTDF induced and activated PGC-1a in myocytes, and PGC1a is reported to induce FNDC5, a myokine that drives browning of myf-5-negative white adipocytes (31) . GTDF indeed enhanced FNDC5 expression in C2C12 myotubes and increased its secretion in culture medium (Fig. 7A) , indicating that it might induce FNDC5 in circulation and thereby promote browning of WAT. Histological analysis of eWAT from GTDF-treated db/db mice revealed robust fat mobilization characterized by reduction in adipocyte size (Fig. 7B) , and these eWATs stained strongly for the brown adipose marker UCP-1 (Fig. 7C) , indicating that GTDF indeed induced a browning-like phenomenon.
Adipocyte-specific transgenic overexpression of adiponectin is reported to mobilize WAT, enhance UCPs, and decrease TNF-a and leptin level in this tissue (32), indicating that adiponectin may also promote an FNDC5-independent browning of WAT through a direct action on adipocytes. Differentiation of 3T3L-1 cells in the presence of GTDF from day 0 or day 2 of differentiation reduced oil droplet accumulation in these cells and significantly reduced TG content ( Fig. 7D and E) . Differentiation of 3T3L-1 and mouse (epididymal) or human SVFs in the presence of GTDF enhanced expressions of UCP-1, UCP-2, PGC-1a, brown adipose determination factor PRDM16, brown fat-enriched protein CIDEA, and adiponectin ( Fig. 7F-H) . PRDM16 and C/EBPb transcriptional complex has been implicated in conversion of myf-5-positive myoblasts into BAT (33) , and GTDF also induced the expression of C/EBPb in 3T3L-1 and mouse SVF (Fig. 7H) , indicating that this complex may play an important role in the browning phenomenon observed here. Consistent with elevated browning markers, GTDF increased mitochondrial DNA content in mouse SVFs (Fig. 7I) . Notably, GTDF did not activate b-adrenergic receptors (Supplementary Tables 3 and 4 and Fig. 7J ).
DISCUSSION
After comprehensive molecular characterizations, we have identified GTDF as an orally active, small-molecule adiponectin mimic that improves metabolic parameters in a preclinical disease setting and holds therapeutic promise in metabolic diseases caused by adiponectin deficiency.
GTDF interacted with AdipoRs and displayed a 70-fold higher affinity for AdipoR1 over AdipoR2. It induced adiponectin-associated rapid signaling, gene expressions, and functional events in C2C12 myotubes, which were respectively augmented or abolished by AdipoR1 overexpression or silencing.
Our inability to procure AdipoR knockout mice inspired us to explore alternate model systems and led to the identification of 12-week-old male BKS-db/db mice as AdipoR1 deficient, whereas age-and sex-matched db/db mice were found to be AdipoR1 intact. Intriguingly, these differences were not apparent at the mRNA level but were pronounced in the protein level, especially at the level of PM-associated and hence functional form of AdipoR1 protein. These findings indicate that apart from transcriptional regulation by insulin and Foxo1 (30) , AdipoR1 expression and function may also be regulated by posttranscriptional or -translational events. Interestingly, a recent report characterized a developmentally regulated alternate splice variant of AdipoR1 in human subjects that was strongly enhanced during skeletal muscle differentiation and was decreased in diabetic patients, and the protein level of AdipoR1 accurately represented these changes but not total mRNA levels that accounted for all AdipoR1 splice variants (34) . Our data gains further support from another recent report, which describes that microRNA-221 and the RNA binding protein polypyrimidine tract binding protein regulate AdipoR1 protein expression and are induced in genetic and diet-induced mouse models of obesity (35) .
Consistent with AdipoR1 deficiency, BKS-db/db mice were refractory to GTDF, whereas metabolism in db/db mice was remarkably improved. Interestingly, GTDF reduced feed intake in db/db mice from 16 days onwards. The effect of adiponectin on feed intake is controversial, and all three possible outcomes have been reported (36) (37) (38) . Although the reason for these differences is unclear, strain of mice, mode of administration, and the administered form of adiponectin appear to be responsible. However, it is important to note that we delivered GTDF by oral route, in contrast to systemic delivery or transgene-based overexpression of adiponectin, and thus GTDF may impact satiety-related hormones from the gut. In agreement with this notion, plasma ghrelin level was greatly reduced in GTDF-treated db/db mice. Ghrelin is chiefly produced by P/D1 cells lining the fundus of the stomach, and given the current lack of information regarding expression of AdipoRs in these cells, it is presently unclear if GTDFmediated downregulation of ghrelin level is achieved through AdipoRs in these cells. However, since GTDF did not alter feed intake in adiponectin-insensitive BKSdb/db, it seems probable that these cells may express one or more AdipoRs, which may act as sensors for dietderived putative AdipoR ligands.
In addition to alteration in feed intake, GTDF remarkably reduced nonfasting blood glucose that was (24 h), cells were treated for 6 h with indicated ligands and lysed, and GFP and luciferase activity were determined using a microplate fluorimeter (FLUOstar Omega; BMG Labtech) and a microplate luminometer (GloMax; Promega). The luciferase values were normalized with GFP and plotted as fold luciferase activity over vehicle-treated controls. Data are mean 6 SEM of three independent experiments in all graphs. Images are representative of three independent experiments. GM, growth medium (DMEM with 4.5 mg /mL glucose, 4.0 mmol/L glutamine, 1 mmol/L sodium pyruvate, 10% FBS, and 13 antibiotic-antimycotic solution); DM, differentiation medium (GM supplemented with 1.5 mg/mL insulin, 0.5 mmol/L IBMX, 1.0 mmol/L dexamethasone, and 1 mmol/L rosiglitazone); INS, insulin medium (GM plus 1.5 mg/mL insulin). For human SVFs, after DM and INS medium, cells were cultured for 21 days, at which time, matured adipocyte phenotypes were observed. Cells were given fresh medium containing vehicle or 0.01 mmol/L GTDF every day during the differentiation. *P < 0.05; **P < 0.01; ***P < 0.005.
significant from day 7 onwards and did not fall thereafter. GTDF also stalled the increase in HbA 1c that was observed in vehicle-treated db/db mice. Reduction in feed intake could not account for these changes as earlier reports have demonstrated that caloric restriction not only fails to decrease nonfasting blood glucose or HbA 1c in db/db mice with manifested diabetes (39-41) but also fails to prevent onset of hyperglycemia in db/db mice pair fed for 5 weeks since weaning (42) . That GTDF decreased feed intake in db/db only but not in BL6 and BKS-db/db clearly indicates that toxicity was not involved. It is further supported by our earlier study where GTDF not only normalized feed intake in high-dose dexamethasone-treated Wistar rats but also prevented dexamethsone-induced mortality (20) .
Although the effect of GTDF on nonfasting blood glucose and glucose clearance was robust, it caused a significant but modest decrease in fasting blood glucose and hepatic gluconeogenesis. Since GTDF showed a preference for AdipoR1, and AdipoR2 is the principal AdipoR in liver, it appears that GTDF-mediated reduction of blood glucose might be principally achieved by skeletal muscle AdipoR1-mediated glucose disposal, which is supported by the fact that fasting hepatic glycogen was unaltered upon GTDF treatment. However, a robust reduction in ketone bodies in GTDF-treated db/db mice indicates that in these animals, the liver may efficiently oxidize them.
BKS-db/db display more severe hyperglycemia than db/db and are susceptible to terminal diabetes, characterized by pancreatic b-cell degranulation and death, whereas db/db mice are protected from terminal diabetes due to the unique proliferation capacity of their b-cells (43) . Thus, in older db/db mice, hyperglycemia is corrected through a higher plasma insulin level, although these mice remain severely dyslipidemic (43) . In our experimental setup, consistent with a lower plasma insulin (which was still much higher than healthy BL6) than db/db, the BKS-db/db mice indeed exhibited higher fasting and nonfasting blood glucose. However, b-cell proliferation was not yet apparent in db/db as evidenced by lack of Ki-67 staining, indicating that during the experimental period, the db/db b-cells did not yet go on a proliferative drive. Further, ;30% of b-cells from db/db mice were apoptotic, and GTDF strongly mitigated this apoptosis without increasing proliferation, indicating that GTDF may protect these cells from gluco-and lipotoxic stresses, and a similar finding has been reported for adiponectin (44) .
Despite higher plasma insulin, GTDF-treated db/db mice were not hypokalemic and displayed a remarkably improved lipid profile, evidenced by decreased serum total cholesterol, TG, VLDL, and NEFA and increased HDL, which, together with a marked decline in plasma corticosterone in these mice, indicates that GTDF may have cardioprotective properties. NEFAs are breakdown products of TG that are released from adipocytes after lipolysis and are important in diabetic pathogenesis (45) . The marked decline in plasma NEFAs suggests that in GTDF-treated db/db mice, NEFAs were either used with robust efficiency in liver and skeletal muscle or adipose TG were efficiently oxidized in situ, or a combination of both. These postulates could be corroborated by the facts that livers of GTDF-treated db/db were free from vacuolation and oil droplets, which were characteristically present in vehicle-treated db/db mice, and eWAT depot in GTDF-treated db/db mice showed robust mobilization and increased UCP-1 expression. Since both db/db and BKS-db/db displayed depleted AdipoR1 protein in eWAT, it is possible that GTDF caused browning of eWAT through an indirect mechanism involving the previously described PGC-1a-induced myokine, FNDC5/irisin (31) . Consistent with PGC-1a induction and activation, GTDF induced FNDC5 expression in C2C12 myotubes and its release in culture medium. In addition, GTDF was also capable of directly inducing brown adipose markers and increasing mitochondrial content in 3T3L-1 and mouse and human SVFs differentiated in its presence, indicating that GTDF may protect against energy imbalance-related metabolic diseases. However, further studies including GTDF's effect on energy expenditure are needed to fully understand and realize its potential.
While this article was under review, Okada-Iwabu et al. (46) reported identification and characterization of a smallmolecule AdipoR agonist, AdipoRon. AdipoRon is 2-(4-benzoylphenoxy)-N-[1-(phenylmethyl)-4-piperidinyl]acetamide and GTDF is a flavone c-glucoside, and these compounds do not share any structural homology. Functionally, AdipoRon showed comparable affinity to both AdipoR1 and -2 and acted through both these receptors to bring about physiological improvements in diabetic mice, whereas GTDF showed a stronger affinity for AdipoR1, and given its modest effects on hepatic gluconeogenesis, appears to act mainly via AdipoR1. Incidentally, another recent report identified DHQ (also known as taxifoliol) as one of nine small-molecule AdipoR agonists from a library of 10,000 compounds by a fluorescent polarization-based screen; however, the in vivo efficacy of DHQ is yet to be elucidated (47) . DHQ is an enantiomer of the aglycone form of GTDF and was active in our PPARa ligand activation as well, albeit at a 10-fold higher concentration than GTDF. In contrast to GTDF, DHQ displays a stronger affinity for AdipoR2 (47) , and thus studies with DHQ alone or in combination with GTDF will be needed to further explore their therapeutic potential in metabolic diseases.
In conclusion, discovery of GTDF as a small-molecule adiponectin mimetic that remarkably improves metabolic health in diabetic mice provides a promising therapeutic tool for treatment of adiponectin deficiency-associated metabolic diseases. However, given the lack of AdipoR knockout animal models in this study, it remains to be confirmed if all the beneficial metabolic effects of GTDF were indeed routed through AdipoRs alone.
